Nothing works in dialysis - except fis oil. Truly amazing data from the PISCES. Should we begin perscribimg fish oil supplements to all our dialysis patients? In spite of my somewhat sceptical priors, I think the answer should be “yes” #NephSky #KidneyWk #nephrology

Ian McCoy describing higher rates of intradialytic hypotension with more frequent HD in AKI-D including the fresh off the press LIBERATE-D. #kidneywk

From 2011 to 2020, chronic kidney disease affected 14.6% of US adults and 16.7% with cardiometabolic conditions, yet only 13% were aware of their diagnosis; awareness was lowest in younger adults, women, and Hispanic adults. #AHA25 @ahascience.bsky.social ja.ma/4hXARmk

💬 Invited Commentary: Chronic kidney disease (#CKD) amplifies cardiovascular risk, yet therapeutic inertia and low disease awareness persist. New CKM syndrome data reveal persistently low CKD recognition. #AHA25 @ahascience.bsky.social ja.ma/4otDIWj

After AKI, don’t forget cardioprotective meds 💊 Observational data show restarting ACEi/ARB within 3–6 months is linked to lower mortality, while SGLT2i & statins also reduce death/CKD progression. Reintroduce when indicated, monitor K+ & kidney function. #AKI #KidneyWk

Pediatric renalism - it’s little bit worse than just renalism see below #Kidneywk #NephSky

Summary from the #NephJC team of day 3 www.nephjc.com/news/2025/11... Since we had only two trials simul-published today at #KidneyWk we took some creative license on what to include ! @nephroseeker.medsky.social with the beautiful graphics and tables apart from the lion’s share of writing!

What about hypERkalemia? #kidneywk

Cui for a study of membranous with MIL62 #KidneyWk

Dietary potassium can be good for you. AND there is little to no correlation btwn dietary K intake & serum K level (even in pts w/ CKD). #Kidneywk

Busting some delusions about #longcovid open.substack.com/pub/christos... (Also on X/Twitter and Mastodon)

Which antihypertensive agents should be used in Thoracic Aorta Dissection? 🔗 academic.oup.com/ajh/advance-... #WeekendReads from the Advance Articles section

Indications for mineralocorticoid receptor antagonists (MRAs) in the management of cardio-kidney risk #KidneyWk #Nephpearls #NephSky #Cardiorenal ✅ Check out this resource from @theisn.org @isnkidneycare.bsky.social 👉 www.theisn.org/initiatives/...

Missing all the overwhelming amount of science coming out of #KidneyWk? The #NephJC crew has got you covered Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi

And in the evening - a CAR T in refractory SLE - a PKD trial - increasing PD in Vets - Povetacicept in IgA - TESTING Longterm term data - what do the AHA/ACC BP guidelines mean? #KidneyWk

Today’s LBCTs and late breaking science! Morning: - an Alport trial! - Telitacicept - REGENCY biopsy data - Vitamin R updated in Membranous - another sibeprenlimab slice - Balcinrenine + Dapa in CKD #KidneyWk

Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles #nephrology #nephsky link.springer.com/article/10.1...

Sodium-glucose cotransporter 2 inhibitors—but not insulin—enhance renal branched-chain amino acid catabolism #nephsky #nephrology www.frontiersin.org/journals/end...

Flashback #FluorescenceFriday to some of the first light-sheet imaging we were doing. Video shows the collecting duct system of the developing kidney labeled with a pan-cytokeratin antibody. Courtesy of former talented technician Deanna Hardesty.

#KidneyWk: In patients with #MPO)-#ANCA-associated vasculitis (#AAV) who are in #LTROT, an increased number of B regulatory cells and a greater repopulation of autoantigen-specific B cells have been observed. Read more: https://bit.ly/43koEC2 #KidneyWeek #RareDisease #Nephrology #MedSky

Shock care: diagnose early & target physiology. Use multimodal endpoints (CRT, urine, mentation; lactate; MAP/ScvO₂/v-a CO₂ gap). Give fluids dynamically—stop when non-responsive. Aim guideline MAP. Start vasoactives early, matched to physiology. #KidneyWk

25 patients with type 4 collagen variants were enrolled in the DUPLEX study. Sparsentan treated patients had lower proteinuria compared to irbesartan control. #KidneyWk

Study Reveals Mismatch in Kidney Function Tests Linked to Major Health Risks#USA#New_York#kidney_function#creatinine#cystatin_C

Fluid overload: recognize it at the bedside—rapid weight gain, pitting edema, crackles, ↑JVP, ascites. Labs can help; BNP/proBNP are most specific, many others are dilutional. Follow trends (not single values) and correlate with history, exam & imaging. #KidneyWk

Invasive: CVP: simple trends, poor for fluid responsiveness. PAC: full hemodynamics but invasive; static pressures not predictive. TPTD: CO/GEDV/EVLW—useful but invasive. PWCA: continuous dynamic indices; limits with arrhythmias/vaso-tone. #KidneyWk

#KidneyWk: #FABP4 shows promise as a noninvasive biomarker for monitoring #ANCA-associated glomerulonephritis, the kidney manifestation of #AAV. Read here: https://bit.ly/482Id4n #RareDisease #AAV #KidneyWeek #MedSky

Great start of ‚Hot topics in lupus nephritis’ session chaired by @saynanorouzi.bsky.social and Juan M. Mejia-Vilet, with an excellent lecture of @kronbichlerlab.bsky.social on 25’ treatment targets #KidneyWk @asnkidney.bsky.social

💬 @jama.com Editorial: The LIBERATE-D trial shows conservative dialysis—guided by A-E-I-O-U indications and asking "Why"—promotes earlier kidney recovery and fewer dialysis sessions in AKI. #KidneyWK @asnkidney.bsky.social ja.ma/4hOkM1W

Pediatric patients with primary glomerular diseases may experience faster kidney function decline https://www.newsbeep.com/il/121544/ New research reveals that contrary toconventional belief, primary glomerular diseases are not necessarily benign for children and young adults. In fact, some …

35 children with FSGS were enrolled in the DUPLEX study. Sparsentan treated patients had lower proteinuria and less frequent kidney failure compared to irbesartan control. #KidneyWk

Rethinking my #KidneyWk FOMO.... If day 1 looked promising, day 2 already has 4 sim pub (see tomorrow's #NephJC newsletter). ✍️🔥Lots of reading and writing to do #Nephsky #Medsky

Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial ca. 2025 from @asnpublications.bsky.social #Nephpearls #KidneyWk #NephSky journals.lww.com/jasn/fulltex...

Zubin Modi shares data from Parasol study showing outcomes in children with FSGS are equally as bad as adults. #KidneyWk

Astrid Weins presents unpublished data showing that presence of anti nephrin antibodies doesn’t predict steroid responsiveness in children. #KidneyWk

REMODEL is fantastic demonstration of what we can do with collaborative effort to perform what Kathy Tuttle calls mechanistic clinical trials! Semaglutide provides kidney protection via improvements in inflammation and microvascular function. Lots of data to parse going forward. #KidneyWk

The NAVIGATE-KIDNEY trial: providing CHW support for Hispanic/Latino peeps in @jama.com IM jamanetwork.com/journals/jam... From @cervantes-lily1.bsky.social and team #KidneyWk

Sparsentan reduces proteinuria, slows kidney decline in pediatric FSGS #KidneyWk www.healio.com/news/nephrol...

Astronauts at much higher risk of nephrolithiasis!! 💎 #Kidneywk @weddellite.bsky.social

Excellent talk by Emmanuel Letavernier on iatrogenic/environmental causes of kidney stones. Vitamin C supplementation during COVID pandemic, vitamin D supplementation possible risk factor for Randalls plaques, hair straightening products glyoxylic acid and galore #kidneywk

Fixing a Mismatch: The Case for Age-Aligned Kidney Allocation #nephsky #nephrology www.frontierspartnerships.org/journals/tra...

On the cover, a new analysis of the SELECT trial confirms semaglutide lowers the risk of major heart problems in people who are overweight or obese and already have heart disease, even if they don’t have diabetes. 🫀 Read this & more in our new issue: tinyurl.com/58p97aud

In the afternoon another late breaking oral session among other things at 4:30 pm @brendonneuen.bsky.social Lorundrostat A new oral GLP1 REMODEL to understand sema mechanism GBD kidney disease with @paddymark.bsky.social And @cervantes-lily1.bsky.social ! #KidneyWk

Today’s trials at #KidneyWk In the morning a LBCT session at 10:30 featuring PISCES (fish oil in dialysis!) LIBERATE in AKI Another AKI alerts from @fperrywilson.bsky.social A Transplant trial GLP1 and a Flozin analyses And

AKI take-home: progression drives outcomes—mortality ~2% with no progression vs >70% with dialysis. sCr is late & muscle-dependent (24–120 h). Early biomarkers (NGAL 2–6 h; IL-18/L-FABP) may aid dx (ATN vs HRS/PRA). Need validated cut-points. #AKI #Biomarkers #KidneyWk

sCr is a flawed, delayed AKI signal. NGAL gives actionability: <100–150 μg/gCr minimal injury → optimize volume; 150–220 HRS-AKI±mild ATN → albumin+vasoconstrictor (~70% resp); 220–365 ATN±HRS → trial (~40%); >365 ATN → supportive/consider RRT. #AKI #Biomarkers #KidneyWk

AKI in cirrhosis is common; HRS may be rare but lethal. Differentiate prerenal, HRS-AKI, and ATN—management differs. Pathway: portal HTN → splanchnic VD → ↓effective volume → ↑RAAS/SNS/AVP → renal VC + Na retention. Recognize early. #KidneyWk

Supportive care in cirrhosis + AKI → think VIBES: Volume (IV albumin ~1 g/kg if indicated; paracentesis) • Infection (abx, SBP ppx) • Bleeding (endoscopy ± TIPS) • Encephalopathy (lactulose/rifaximin) • Screening/Surgery (early transplant eval). #KidneyWk

Real-world HRS HARMONY (16 sites; n=243): terlipressin → HRS reversal 30.9% (overall response 54.7%). Safety similar to CONFIRM—resp failure ~9–10%. 90-day transplant 28% and death 40.5% (vs 51% in CONFIRM). Presented at ASN/AASLD 2025. #HRS #KidneyWk

AKI in cirrhosis: check volume early. Albumin x48h → ~40% response; 2 pts had pulmonary edema. If HRS → terlipressin+albumin 61% response; if not HRS → targeted AKI therapy 70%. 19% needed RRT; etiologies: ATN 57%, hypovolemia 25%. #AKI #Cirrhosis #HRS #KidneyWk

RRT in cirrhosis + AKI unresponsive to meds: If transplant-eligible → start RRT, reassess. If not eligible → involve palliative care, clarify goals & feasibility/risks. When burden > benefit or terminal illness → withhold; else use a time-limited trial. #KidneyWk